Total salvage therapy for refractory acute promyelocytic leukemia (APL) including arsenic trioxide (AS203), all trans-retinoic acid (ATRA) and mylotarg [gemtuzumab ozogamicin]
Phase of Trial: Phase I
Latest Information Update: 08 Dec 2005
At a glance
- Drugs Arsenic trioxide (Primary) ; Gemtuzumab ozogamicin (Primary) ; Tretinoin (Primary)
- Indications Acute promyelocytic leukaemia
- Focus Therapeutic Use
- 08 Dec 2005 New trial record.